Protagonist Therapeutics (PTGX) Leases (2019 - 2025)
Historic Leases for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $8.2 million.
- Protagonist Therapeutics' Leases fell 1688.87% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 1688.87%. This contributed to the annual value of $9.4 million for FY2024, which is 88710.69% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' Leases is $8.2 million, which was down 1688.87% from $8.6 million recorded in Q2 2025.
- Over the past 5 years, Protagonist Therapeutics' Leases peaked at $10.3 million during Q2 2024, and registered a low of $387000.0 during Q1 2024.
- For the 5-year period, Protagonist Therapeutics' Leases averaged around $5.1 million, with its median value being $4.5 million (2022).
- Its Leases has fluctuated over the past 5 years, first crashed by 8485.92% in 2024, then surged by 222558.14% in 2025.
- Quarter analysis of 5 years shows Protagonist Therapeutics' Leases stood at $4.9 million in 2021, then plummeted by 37.99% to $3.1 million in 2022, then plummeted by 68.83% to $954000.0 in 2023, then skyrocketed by 887.11% to $9.4 million in 2024, then dropped by 13.2% to $8.2 million in 2025.
- Its Leases stands at $8.2 million for Q3 2025, versus $8.6 million for Q2 2025 and $9.0 million for Q1 2025.